Based on this mechanism, a phase 2 trial was conducted evaluating the safety and feasibility of chemo-immunotherapy using these AKT-DCs in post-surgical N2 NSCLC patients (66). The gene discussed is AKT1; the disease is non-small cell lung carcinoma.